EA201992812A1 - Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери - Google Patents

Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери

Info

Publication number
EA201992812A1
EA201992812A1 EA201992812A EA201992812A EA201992812A1 EA 201992812 A1 EA201992812 A1 EA 201992812A1 EA 201992812 A EA201992812 A EA 201992812A EA 201992812 A EA201992812 A EA 201992812A EA 201992812 A1 EA201992812 A1 EA 201992812A1
Authority
EA
Eurasian Patent Office
Prior art keywords
releasing hormone
blood loss
menstrual blood
gonadotropine
diagrams
Prior art date
Application number
EA201992812A
Other languages
English (en)
Russian (ru)
Inventor
Эрнест Лумайе
Жан-Пьер Готтеланд
Оливье Поль
Original Assignee
Обсева С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Обсева С.А. filed Critical Обсева С.А.
Publication of EA201992812A1 publication Critical patent/EA201992812A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EA201992812A 2017-06-05 2018-06-05 Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери EA201992812A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Publications (1)

Publication Number Publication Date
EA201992812A1 true EA201992812A1 (ru) 2020-05-21

Family

ID=62636157

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992812A EA201992812A1 (ru) 2017-06-05 2018-06-05 Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери

Country Status (18)

Country Link
US (2) US11759464B2 (https=)
EP (2) EP3634419B1 (https=)
JP (2) JP7292566B2 (https=)
KR (1) KR102884301B1 (https=)
CN (1) CN110996957A (https=)
AU (2) AU2018280741B2 (https=)
CA (1) CA3066188A1 (https=)
DK (1) DK3634419T3 (https=)
EA (1) EA201992812A1 (https=)
ES (1) ES3018358T3 (https=)
FI (1) FI3634419T3 (https=)
HR (1) HRP20250390T1 (https=)
HU (1) HUE070907T2 (https=)
MX (2) MX2019014482A (https=)
PL (1) PL3634419T3 (https=)
PT (1) PT3634419T (https=)
SG (1) SG11201911599XA (https=)
WO (1) WO2018224497A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) * 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
CN114466665A (zh) * 2019-08-08 2022-05-10 奥布赛瓦股份公司 用于治疗雌激素依赖性病症的组合物和方法
AU2020325721A1 (en) * 2019-08-08 2022-03-03 ObsEva S.A. GnRH antagonists for the treatment of estrogen-dependent disorders
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
KR101384132B1 (ko) 2005-10-19 2014-04-10 깃세이 야쿠힌 고교 가부시키가이샤 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
SG183243A1 (en) * 2010-02-10 2012-09-27 Kissei Pharmaceutical Salt of fused heterocyclic derivative and crystal thereof
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
US10881659B2 (en) * 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
TWI746613B (zh) 2016-08-08 2021-11-21 日商橘生藥品工業股份有限公司 子宮內膜病症治療劑之用法及用量
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders

Also Published As

Publication number Publication date
EP4509173A3 (en) 2025-06-04
EP3634419B1 (en) 2025-01-29
JP2023078315A (ja) 2023-06-06
CA3066188A1 (en) 2018-12-13
KR20200024797A (ko) 2020-03-09
EP4509173A2 (en) 2025-02-19
HRP20250390T1 (hr) 2025-05-23
CN110996957A (zh) 2020-04-10
MX2019014482A (es) 2020-08-17
SG11201911599XA (en) 2020-01-30
PT3634419T (pt) 2025-04-04
PL3634419T3 (pl) 2025-06-09
AU2018280741A1 (en) 2020-01-30
JP2020522525A (ja) 2020-07-30
AU2024201694A1 (en) 2024-04-04
KR102884301B1 (ko) 2025-11-11
WO2018224497A1 (en) 2018-12-13
ES3018358T3 (es) 2025-05-16
HUE070907T2 (hu) 2025-07-28
FI3634419T3 (fi) 2025-05-02
US20200179390A1 (en) 2020-06-11
JP7292566B2 (ja) 2023-06-19
MX2023013582A (es) 2024-04-16
JP7485815B2 (ja) 2024-05-16
EP3634419A1 (en) 2020-04-15
US11759464B2 (en) 2023-09-19
US20240000785A1 (en) 2024-01-04
AU2018280741B2 (en) 2023-12-21
DK3634419T3 (da) 2025-03-31

Similar Documents

Publication Publication Date Title
EA201992812A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
WO2020094698A3 (en) Compositions and methods for the treatment of estrogen-dependent disorders
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
EA202090577A2 (ru) Соматотропный гормон пролонгированного действия и способы его получения
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
EA201791607A1 (ru) Циклические динуклеотиды, полезные для лечения среди прочего рака
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
NO20056251L (no) Pyrimidin-2,4-dionderivater som gonadotropin-frigjorende hormon reseptor antagonist
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
EP4335497A3 (en) Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
EA201990249A1 (ru) Применение и режим дозирования терапевтических агентов при эндометриозе
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
PH12019501016A1 (en) Treatment of cns diseases with sgc stimulators
NZ601684A (en) Salt of fused heterocyclic derivative and crystal thereof
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
DK1885333T3 (da) Farmaceutisk formulering af apomorphin til bukkal indgivelse
WO2010099003A3 (en) Compositions and methods for visualizing and eliminating cancer stem cells